Suggestions for secondary innovations and generic development for drugs from the perspective of patent — taking HIV protease inhibitor lopinavir as an example

YANG Qian; MA Qiujuan; WANG Xiaojian

doi:10.11665/j.issn.1000-5048.20150419

Journal of China Pharmaceutical University > 2015 > 46(4): 499-503. > DOI: 10.11665/j.issn.1000-5048.20150419

YANG Qian, MA Qiujuan, WANG Xiaojian. Suggestions for secondary innovations and generic development for drugs from the perspective of patent — taking HIV protease inhibitor lopinavir as an example[J]. Journal of China Pharmaceutical University, 2015, 46(4): 499-503. DOI: 10.11665/j.issn.1000-5048.20150419

Citation:

PDF (1055 KB)

Suggestions for secondary innovations and generic development for drugs from the perspective of patent — taking HIV protease inhibitor lopinavir as an example

More Information

Graphical Abstract

Abstract

Abstract

Protease inhibitors(PIs)are a class of antiviral drugs widely used for the treatment of HIV/AIDS. The status of intellectual property of HIV protease inhibitors lopinavir is briefly reviewed in this paper. Based on the indication of Kaletra^®, the follow-up studies and generic development of PIs were discussed. It was concluded that the combination of PIs and anti-bacterial/anti-fungal drugs with CYP450 inhibitory effects would be of great use for AIDS and the infectious complications, in the hope of seeking the secondary innovation of other drugs with expired patents in the fields of drug combination and indication expansion.
- patent,
- drug development,
- protease inhibitors,
- lopinavir,
- drug combination

FullText(HTML)

References (11)

References

[1]	Yang QG,He XC,Bai DL.Current status of HIV protease inhibitors[J].Acta Pharm Sin(药学学报),2005,40(5):389-394.
[2]	Guo DL, Liu GN, Li J, et al. Improved synthesis of raltegravir[J].J China Pharm Univ(中国药科大学学报),2009,40(4):297-301.
[3]	Molla A,Mo HM,Vasavanonda S,et al.In vitro antiviral interaction of lopinavir with other protease inhibitors[J].Antimicrob Agents Ch,2002,46(7):2249-2253.
[4]	Liu J,Dong L.The discussion of generic drugs development for Chinese pharmaceutical enterprises[J].Chin Pharm(中国药业),2011,20(16):6-7.
[5]	Guo ZR,Zhao HY.Challenges and strategies of drug innovation[J].Acta Pharm Sin(药学学报),2013,48(7):1031-1040.
[6]	Aids Map.Fixed-dose combinations[EB/OL].(2011-03-31)[2014-04-09] .http://www.aidsmap.com/Fixed-dosecombinations/page/1729748/.
[7]	Walmsley S.Protease inhibitor-based regimens for HIV therapy:safety and efficacy[J].J Acq Imm Def Syn,2007,45(S1):S5-13.
[8]	Du HZ,Yang Q,Song JY,et al.Research toward approved drugs for anti-HIV/acquired immunodeficiency syndrome and its complications[J].Chin Pharm J(中国药学杂志),2009,44(2):81-87.
[9]	U.S.Food and Drug Administration.Drug development and drug interactions:table of substrates,inhibitors and inducers[EB/OL].(2006-05-01)[2014-05-20] .http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#classInhibit.
[10]	Sanso G.Double capsule for the administration of active principles in multiple therapies:US,6350486B1[P].2002-02-26[2014-05-25] .
[11]	Wu JJ,Stranix BR,Ge M,et al.Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors:US,2012/0053139A1[P].2012-05-01[2014-05-25] .

Cited By

Get Citation

PDF

XML

Article views (1190) PDF downloads (2931)

Turn off MathJax

Article Contents

Abstract

References

Suggestions for secondary innovations and generic development for drugs from the perspective of patent — taking HIV protease inhibitor lopinavir as an example

Abstract

References

Catalog

Export File

Citation

Format

Content